Bio Medica Laboratories Reports Deviations in IPO Proceeds Utilization for H1FY27
Bio Medica Laboratories Ltd · Others (Uncategorized) · 14 Nov 2026, 9:27 pm
Bio Medica Laboratories Reports Deviations in IPO Proceeds Utilization for H1FY27 CARE Ratings flagged deviations in Bio Medica Laboratories' IPO proceeds utilization for the half-year ended 30th Sep'26. The company utilized ₹22.77 crore out of ₹47.19 crore fresh issue proceeds. Key deviations include General Corporate Purpose spending of ₹9.09 crore against an allocated ₹7.05 crore, loan repayments of ₹6.54 crore versus ₹6.50 crore, and capex deployment of ₹2.21 crore including ₹0.1965 crore GST. The company will rectify deviations by transferring ₹2.2765 crore from internal accruals back to the Monitoring Account by 30th Nov'26.
Original exchange filing (PDF)
More announcements from Bio Medica Laboratories Ltd
- Bio Medica Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 13 Nov 2026
- Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report of the Company for the half year ended September 30, 2026 in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) 2015. · 13 Nov 2026
- Bio Medica Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 13 Nov 2026
- Bio Medica Laboratories Limited has informed the Exchange about Board Meeting to be held on 13-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 13 Nov 2026
- BMLL : 13-Nov-2026 : The Company has informed the Exchange that a Board meeting to be held on November 05, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on November 13, 2026, To consider and approve the financial results for the period ended September 30, 2026 · 13 Nov 2026
- Bio Medica Laboratories Limited has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 05 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 · 05 Nov 2026
- Non-Applicability of Corporate Governance Report for the 2nd Quarter Ended on 30th September, 2026. · 26 Oct 2026
